SUMOylation proteins in breast cancer

Breast Cancer Research and Treatment

Volumn 144, Issue 3, 2014, Pages 519-530

  Alshareeda, Alaa T ^a,b   Negm, Ola H ^c,d   Green, Andrew R ^a   Nolan, Christopher ^a   Tighe, Paddy ^c   Albarakati, Nada ^c   Sultana, Rebeka ^c   Madhusudan, Srinivasan ^c   Ellis, Ian O ^a   Rakha, Emad A ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Ministry of Education Saudi Arabia   (Saudi Arabia)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Breast cancer; DNA damage response; Immunohistochemistry; Reverse phase protein microarray; SUMOylation; TMA

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; CHECKPOINT KINASE 1; DNA DEPENDENT PROTEIN KINASE; ESTROGEN RECEPTOR; KU ANTIGEN; MEMBRANE PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN KPNA2; PROTEIN PIAS4; PROTEIN UBC9; RAD51 PROTEIN; SUMO PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VOLUME;

ADULT; AGED; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; DNA REPAIR; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; TUMOR BURDEN;

EID: 84899482488     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2897-7     Document Type: Article

References (36)

1. Pinder JB, Attwood KM, Dellaire G (2013) Reading, writing, and repair: the role of ubiquitin and the ubiquitin-like proteins in DNA damage signaling and repair. Front Genet 4:45
2. Bologna S, Ferrari S (2013) It takes two to tango: ubiquitin and SUMO in the DNA damage response. Front Genet 4:106
3. Al-Hakim A et al (2010) The ubiquitous role of ubiquitin in the DNA damage response. DNA Repair (Amst) 9(12):1229-1240
4. Matunis MJ, Coutavas E, Blobel G (1996) A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol 135(6 Pt 1):1457-1470 (Pubitemid 26427644)
5. Mahajan R et al (1997) A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88(1):97-107 (Pubitemid 27180334)
6. Morris JR (2010) More modifiers move on DNA damage. Cancer Res 70(10):3861-3863
7. Mo YY et al (2005) A role for Ubc9 in tumorigenesis. Oncogene 24(16):2677-2683
8. Moschos SJ, Mo YY (2006) Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis. J Mol Histol 37(5-7):309-319 (Pubitemid 44795634)
9. Moschos SJ et al (2010) Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol 41(9):1286-1298
10. Hoefer J et al (2012) PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol 180(5):2097-2107
11. Agboola A et al (2013) PIASgamma expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. J Clin Pathol. doi:10.1136/jclinpath-2013-201658
12. Alshareeda AT et al (2013) Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast Cancer Res Treat 139(2):301-310
13. Rakha EA et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495-506
14. Rakha EA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302-2310
15. Alshareeda AT et al (2012) Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. Breast Cancer Res Treat 134(2):519-529
16. Aleskandarany MA et al (2012) Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 14(1):R3
17. Bergink S, Jentsch S (2009) Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458(7237):461-467
18. Sachdev S et al (2001) PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 15(23):3088-3103 (Pubitemid 33115674)
19. Sentis S et al (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19(11):2671-2684 (Pubitemid 41577242)
20. Morris JR et al (2009) The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 462(7275):886-890
21. Qin Y et al (2011) Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins. J Cell Physiol 226(12):3355-3367
22. Chen SF et al (2011) Ubc9 expression predicts chemoresistance in breast cancer. Chin J Cancer 30(9):638-644
23. Agboola AO et al (2014) Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women. Pathol Res Pract 210(1):10-17
24. Clevenger CV (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165(5):1449-1460
25. Wei J et al (2011) mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 103(20):1552-1556
26. Coppola D et al (2009) Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol 135(9):1287-1291
27. Baek SH (2006) A novel link between SUMO modification and cancer metastasis. Cell Cycle 5(14):1492-1495
28. Chook Y, Blobel G (2001) Karyopherins and nuclear import. Curr Opin Struct Biol 11(6):703-715
29. Xu J et al (2009) A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells. Int J Oncol 34(4):939-949
30. Martin RW et al (2007) RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 67(20):9658-9665 (Pubitemid 47621212)
31. Abdel-Fatah TM et al (2010) The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 220(4):419-434
32. Aleskandarany MA et al (2011) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 127(3):591-599
33. Kahyo T, Nishida T, Yasuda H (2001) Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell 8(3):713-718 (Pubitemid 32946947)
34. Park MA et al (2008) SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancy. Nucleic Acids Res 36(1):263-283
35. Cortez D et al (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286(5442):1162-1166
36. Mohanty S et al (2014) ROS-PIASgamma cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors. Cell Death Dis 5:e1021